Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics' INT230-6 (PORT-1) at November Scientific Conferences
Stock Information for Portage Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.